| Code | CSB-RA003995MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to ALXN-5500, targeting complement component 5 (C5), a critical protein in the complement cascade of the innate immune system. C5 plays a pivotal role in immune defense by facilitating the formation of the membrane attack complex (MAC) and generating the potent anaphylatoxin C5a upon cleavage. Dysregulated C5 activation contributes to numerous complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis, and neuromyelitis optica spectrum disorder (NMOSD). Excessive C5 activity drives pathological inflammation, cell lysis, and tissue damage in these conditions.
ALXN-5500 (ravulizumab) is a long-acting C5 inhibitor that prevents cleavage of C5 into C5a and C5b, thereby blocking MAC formation and downstream inflammatory responses. This biosimilar antibody provides researchers with a valuable tool for investigating complement-mediated pathophysiology, evaluating therapeutic mechanisms in complement-driven diseases, and developing novel intervention strategies. It supports studies examining C5 biology, complement system regulation, and disease modeling in relevant experimental systems.
There are currently no reviews for this product.